SCHEMBL15325873

SCHEMBL15325873

Cc1ccc2c(cnn2C2CCNCC2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.52
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
PKM P14618 1/20 0.43
ALOX15 P16050 1/20 0.43
KMT2A Q03164 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
CHRNB2 P17787 2/20 0.42
CHRNA4 P43681 2/20 0.42
POLB P06746 1/20 0.42
IRAK4 Q9NWZ3 2/20 0.40
KHK P50053 1/20 0.40
BRD4 O60885 2/20 0.40
JAK2 O60674 1/20 0.40
JAK1 P23458 1/20 0.40
NSD3 Q9BZ95 1/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
BRD2 P25440 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL15655447 0.98 KDM1A (0.51) KDM1AMEN1ALDH1A1MAPTPKM
SCHEMBL13432159 0.91 POLB (0.45) KDM1APOLBCYP11B1CYP11B2GPR119
SCHEMBL15830291 0.90 KDM1A (0.51) KDM1AMEN1ALDH1A1MAPTPKM
SCHEMBL24282841 0.86 POLB (0.48) KDM1AALDH1A1MAPTTDP1POLB
SCHEMBL15345104 0.84 PDE1A (0.51) POLB
SCHEMBL1871485 0.82 ALDH1A1 (0.50) KDM1AMEN1ALDH1A1MAPTPKM
SCHEMBL21060754 0.82 MEN1 (0.43) KDM1AMEN1ALDH1A1MAPTPKM
SCHEMBL10060682 0.82 MEN1 (0.43) KDM1AMEN1ALDH1A1MAPTPKM
SCHEMBL30450183 0.82 MEN1 (0.43) KDM1AMEN1ALDH1A1MAPTPKM
SCHEMBL15701837 0.81 GPR119 (0.46) KDM1AMEN1ALDH1A1MAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160355511-A1 NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2016-12-08 US disclosed
US-20160355511-A1 NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2016-12-08 US disclosed
US-9309221-B2 1-substituted indazole derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2016-04-12 US disclosed
US-9309221-B2 1-substituted indazole derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2016-04-12 US disclosed
US-9051295-B2 1-substituted indazole derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2015-06-09 US disclosed
US-9051295-B2 1-substituted indazole derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2015-06-09 US disclosed
EP-2837623-A1 NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE Sumitomo Dainippon Pharma Co., Ltd. (JP) 2015-02-18 EP disclosed
US-20150031681-A1 NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2015-01-29 US disclosed
US-20150031681-A1 NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2015-01-29 US disclosed
US-8765786-B2 1-substituted indazole derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2014-07-01 US disclosed
US-8765786-B2 1-substituted indazole derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2014-07-01 US disclosed
US-20140121244-A1 NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2014-05-01 US disclosed
US-20140121244-A1 NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2014-05-01 US disclosed
US-20140121243-A1 NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2014-05-01 US disclosed
US-20140121243-A1 NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2014-05-01 US disclosed
WO-2013154109-A1 NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE 大日本住友製薬株式会社 (JP) 2013-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140121244-A1 NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE CHRNA3, CHRNB3, CHRNA7 KDM1A 1384/4885MEN1 3511/4885ALDH1A1 2666/4885
US-20160355511-A1 NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE CHRNA3, CHRNB3, CHRNA7 KDM1A 1384/4885MEN1 3511/4885ALDH1A1 2666/4885
US-20140121243-A1 NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE CHRNA3, CHRNB3, CHRNA7 KDM1A 1384/4885MEN1 3511/4885ALDH1A1 2666/4885
US-20150031681-A1 NOVEL 1-SUBSTITUTED INDAZOLE DERIVATIVE CHRNA3, CHRNB3, CHRNA7 KDM1A 1384/4885MEN1 3511/4885ALDH1A1 2666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.